Why Corporate Giants Buy Instead of Build

On Monday morning, the market delivered its verdict on the largest pharmaceutical combination ever proposed. AstraZeneca shares fell 7% after the Financial Times reported that the UK drugmaker had held preliminary talks with Bristol Myers Squibb about a merger that would value the combined company at nearly $400 billion. AstraZeneca is the second-biggest listed company in the UK, with a market value close to £196 billion, and Bristol Myers is one of America's oldest drugmakers. The share drop captures the tension at the center of modern dealmaking: buying has become the default path to growth, and investors are no longer certain the price is justified.

The talks, which Reuters confirmed citing a source, may still collapse. A deal of this size would trigger one of the most consequential antitrust reviews in pharmaceutical history, and neither company has confirmed an intention to proceed. But the conversation itself is the story. When two of the world's largest drug companies conclude that the fastest route to scale runs through a checkbook rather than a laboratory, the economics of building have fundamentally changed.

A Merger That Would Reshape Global Pharma

The proposed tie-up would rank among the largest deals in any industry in any era. Combining AstraZeneca's oncology and respiratory franchises with Bristol Myers' immunology and cell therapy portfolio would create a group with pricing power that governments in Washington, London, and Brussels would scrutinize for years. The discussions are preliminary and may not lead to a transaction, but the market response was immediate: AstraZeneca's stock dropped sharply on Monday while Bristol Myers shares climbed, according to CNBC.

The divergence in the two share prices is a window into how the market prices buy versus build. Bristol Myers shareholders were handed a premium on their stake in the form of merger speculation, while AstraZeneca shareholders were handed the prospect of years of integration complexity, antitrust risk, and a heavier balance sheet. Whether dominance, purchased at this price, beats what the two companies could have achieved alone is the open question the deal would answer.

Pharma is the purest laboratory for this question because the alternative to buying is so slow. Developing a new drug takes more than a decade from discovery to approval, and most candidates fail in clinical trials. A company that needs a new revenue stream by the early 2030s can't wait for its own pipeline to deliver one. It buys someone else's pipeline, along with the clinical teams, the manufacturing capacity, and the regulatory relationships that took decades to assemble.

The Math of Buying Time

The management consulting framework that corporate boards have leaned on for decades frames the choice in deceptively simple terms. Building is cheaper on paper and preserves full control, but it takes longer and carries execution risk. Buying costs more upfront, yet it delivers revenue, talent, and market position on day one. In a world where interest rates were near zero, the patient path made sense, because cheap capital meant a company could fund a decade of internal development and still come out ahead.

That world is gone, replaced by a regime in which capital costs more and technology cycles move faster. Every quarter a company spends building is a quarter in which a rival can buy the same capability outright and bring it to market immediately. When the constraint is time rather than money, the acquisition premium becomes a rational price for speed. The same logic that pushed companies to buy AI capability rather than assemble it in-house now applies across entire industries.

The shift is visible in how boards now talk about acquisition strategy. The old rationale was diversification, spreading risk across businesses a company didn't fully understand. The new rationale is concentration, buying exactly the capability a company needs and integrating it fast. Private equity firms have followed the same playbook, assembling platforms through serial acquisitions rather than single bets, a model the industry calls buy and build. The goal is the same as it is for AstraZeneca: compress the time between decision and revenue.

The Great Rebound of 2025

The data from last year shows how completely the pendulum has swung. Global M&A activity reached $4.8 trillion in 2025, up 41% from 2024 and the second-highest total on record, according to Bain & Company's annual deal report. The number of transactions fell, but the size of each one grew, with a record number of deals exceeding $10 billion. These were defensive and structural deals: companies buying scale, supply chains, and strategic positions in an environment defined by tariffs, trade shocks, and geopolitical fragmentation.

The rebound was led by the technology sector, with AI and related infrastructure absorbing the largest share of capital, and by defense, where consolidation accelerated as governments across Europe and Asia rebuilt capacity after years of underinvestment. Energy security drove a third wave, as utilities and industrials acquired the grid capacity, battery technology, and critical mineral assets they couldn't build fast enough to meet demand. Each of these sectors shares a common feature: the asset being acquired is scarce, and the time required to reproduce it internally is measured in years.

This is the defining characteristic of the current cycle, and deal advisers describe it as a K-shaped recovery. Strategic buyers with strong balance sheets are transacting at record levels, while weaker companies and leveraged players are being priced out of the market. The result is a consolidation dynamic in which the biggest companies get bigger through acquisition, and the gap between the top of the market and everyone else widens with every deal.

Financing Is Available. For Now.

The reason this strategy has been able to run is that the money is there. Financing conditions stabilized through late 2025 and into 2026, with private capital preparing for a strong year of activity and strategic buyers seeking to reposition through large deals, a forecast Clifford Chance laid out in its outlook for the year. Sarah Jones, the firm's global head of corporate, has said the optimism could be tempered by geopolitical tensions or a tightening of credit markets.

That caveat is the one to watch this week and through the rest of the summer. The yen's slide has already forced the US and Japan into a rare joint intervention to prop up the currency, and oil markets are reacting to shifting signals on the Iran situation. None of that stops a deal that is already in motion, but it changes the price of the debt needed to finance the next one. If credit tightens, the buy instead of build calculus shifts again, and the advantage swings back toward companies with the patience and the balance sheet to build.

The availability of capital is not evenly distributed. Investment-grade strategics can borrow at rates that make large deals accretive, while smaller buyers depend on leveraged loan markets that have become pickier about risk. That asymmetry reinforces the concentration dynamic: the companies that can afford to buy are the same ones getting bigger, and the financing window, open today, has a history of closing quickly when volatility returns.

The Risk No Premium Can Remove

The AstraZeneca share move on Monday is a useful reminder that acquisition premiums don't insure against execution failure. Most mergers destroy value, a finding that has held across decades of research, because integration is where the value leaks: culture clashes, lost talent, duplicated costs, and management distraction. The bigger the deal, the harder the integration, and a $400 billion merger would be the hardest integration in corporate history.

There is also the question of what the price actually buys. A combined AstraZeneca and Bristol Myers would inherit overlapping research programs, two sales forces in the same therapeutic areas, and the unenviable task of merging distinct corporate cultures across the Atlantic. The largest mergers in pharma history have delivered mixed returns to shareholders, and the premium paid up front is rarely recovered in full. Monday's share move suggests investors have internalized that history.

The skepticism on display was about execution, not strategy. Scale in pharma is a well understood advantage, and the logic of combining these two portfolios is not difficult to follow. What is difficult is the follow-through, and the market is pricing the probability that the follow-through fails.

Every previous era of consolidation eventually collided with antitrust enforcement, and this cycle has already attracted scrutiny in Washington and Brussels. If regulators decide that scale itself is the problem, the buy instead of build strategy loses its cheapest input: certainty that the deal will close. Until that question is answered, the record pace of dealmaking will keep running on momentum, and the premium for time will keep rising.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Past performance is not indicative of future results. Consult a qualified financial advisor before making investment decisions.